Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical's stock performance and financial metrics indicate a challenging period, with significant declines in revenue and net profit, alongside high financing levels [1][2]. Group 2 - On December 23, Duorui Pharmaceutical's stock rose by 3.14%, with a trading volume of 72.61 million yuan. The financing buy-in amount was 3.21 million yuan, while the financing repayment was 7.48 million yuan, resulting in a net financing buy of -4.28 million yuan [1]. - As of December 23, the total financing and securities lending balance for Duorui Pharmaceutical was 209 million yuan, accounting for 5.08% of its market capitalization, which is above the 90th percentile level over the past year [1]. - The company has not engaged in securities lending activities on December 23, with no shares sold or repaid, indicating a high level of inactivity in this area [1]. - Duorui Pharmaceutical, established on December 22, 2016, and listed on September 29, 2021, focuses on the research, production, and sales of chemical drug formulations and their raw materials. The revenue composition is as follows: formulations 37.60%, intermediates 35.78%, raw materials 21.64%, and others 4.98% [1]. - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period, while the average circulating shares per person increased by 19.90% to 12,576 shares [2]. - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%, and a net profit attributable to shareholders of -79.73 million yuan, representing a year-on-year decline of 366.82% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].

Core Viewpoint - The company, Duori Pharmaceutical (301075.SZ), has announced a plan to repurchase shares through a concentrated bidding method, which will be followed by a reduction in shareholding [1] Group 1: Share Repurchase Plan - The board of directors has approved a proposal regarding the share repurchase and subsequent reduction plan [1] - The company intends to sell back the repurchased shares within a period of six months, starting from 15 trading days after the announcement [1] - The maximum number of shares to be sold is 1.0445 million, which represents 1.31% of the company's total share capital [1] Group 2: Sale Conditions - The sale price of the repurchased shares will be determined based on the secondary market price [1] - The implementation period for the sale is set from January 14, 2026, to July 13, 2026, excluding any periods prohibited by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) announced the plan to sell repurchased shares through a centralized bidding method, with a total of up to 1,044,500 shares, representing 1.31% of the company's total share capital [1] Group 1 - The sale period for the repurchased shares will be from January 14, 2026, to July 13, 2026, excluding the periods prohibited by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [1] - The selling price of the repurchased shares will be determined based on the secondary market price [1]

Group 1 - The core viewpoint of the article is that Duorui Pharmaceutical (301075.SZ) has decided to terminate several fundraising projects and return the remaining funds to repay bank loans and supplement working capital permanently [1] - The company has approved the termination of the following projects: "Annual production of 16 million bags of sodium acetate injection (Phase III project)", "New product development project", and "Tibet headquarters and R&D center construction project" [1] - The project "Academic promotion and marketing network expansion project" has been concluded [1] Group 2 - To implement the termination of the aforementioned fundraising projects, Hubei Duorui plans to reduce its registered capital by 241.9 million yuan [1] - After the capital reduction, Hubei Duorui's registered capital will change from 271.9 million yuan to 30 million yuan [1]

多瑞医药(301075.SZ)公告，公司董事会审议通过了《关于回购股份集中竞价减持计划的议案》，根据 公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方式出售已回购股份,实 施期限为自本公告披露之日起15个交易日后的6个月内(即2026年1月14日至2026年7月13日，根据中国证 监会及深圳证券交易所相关规定禁止出售的期间除外)，本次拟出售回购股份不超过104.45万股，占公 司总股本的1.31%，出售价格根据二级市场价格确定。 ...

Core Viewpoint - The company, Duori Pharmaceutical (301075.SZ), has approved a share repurchase plan to sell back shares through centralized bidding, with a total of up to 1.0445 million shares, representing 1.31% of the company's total share capital [1] Group 1 - The board of directors has passed a resolution regarding the share repurchase plan [1] - The repurchased shares will be sold within a period starting 15 trading days after the announcement and lasting for 6 months, specifically from January 14, 2026, to July 13, 2026 [1] - The selling price of the repurchased shares will be determined based on the secondary market price [1]

每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 王晓波） 每经AI快讯，多瑞医药（SZ 301075，收盘价：50.9元）12月19日晚间发布公告称，西藏多瑞医药股份 有限公司于2025年12月19日召开第二届董事会第二十五次会议，审议通过了《关于回购股份集中竞价减 持计划的议案》，根据公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方 式出售已回购股份实施期限为自本公告披露之日起15个交易日后的6个月内（即2026年1月14日至2026年 7月13日，本次拟出售回购股份不超过约104万股，占公司总股本的1.31%，出售价格根据二级市场价格 确定。 截至发稿，多瑞医药市值为41亿元。 2024年1至12月份，多瑞医药的营业收入构成为：医药制造业占比57.85%，其他占比42.15%。 ...

西藏多瑞医药股份有限公司 董事及高级管理人员持有本公司股份 第一条 为加强西藏多瑞医药股份有限公司（以下简称"公司"或"本公司"）对董 事和高级管理人员买卖本公司股票及衍生品种的管理，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》（以 下简称"《规范运作指引》"）、《深圳证券交易所上市公司自律监管指引第18号—— 股东及董事、高级管理人员减持股份》、《深圳证券交易所上市公司自律监管指引第 10号——股份变动管理》（以下简称"《监管指引》"）等相关法律、法规、规范性文 件以及《西藏多瑞医药股份有限公司章程》（以下简称"《公司章程》"）的规定，结 合公司客观实际情况，制定本制度。 第二条 公司董事、高级管理人员和证券事务代表在买卖本公司股票及其衍生品 种前，应知悉并遵守《公司法》《证券法》等法律、行政法规、部门规章、规范性文 件、《上市规则》《规范运作指引》和深圳证券交易所（以下简称"深交所"）其他相 关规定中 ...

第三条 审计委员会委员应保证足够的时间和精力履行委员会的工作职责，勤勉尽责， 切实有效地监督公司的外部审计，指导公司内部审计工作，促进公司建立有效的内部控 制并提供真实、准确、完整的财务报告。 西藏多瑞医药股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化西藏多瑞医药股份有限公司（以下简称"公司"）董事会决策功能，做 到事前审计、专业审计，确保董事会对经理层的有效监督，完善公司治理结构，根据相 关规定，特制定本细则。 第二条 董事会审计委员会（以下简称"审计委员会"）是董事会下设的专门委员会， 对董事会负责，向董事会报告工作。 第四条 公司应制定审计委员会工作规程，明确审计委员会的人员构成、委员任期、 职责范围和议事规则等相关事项。 第五条 公司应为审计委员会提供必要的工作条件，配备专门人员或机构承担审计委 员会的工作联络、会议组织、材料准备和档案管理等日常工作。审计委员会履行职责时， 公司管理层及相关部门应给予配合。 第二章 人员组成 第六条 审计委员会成员由三名董事组成，由董事会从董事会成员中任命，审计委员 会成员应当为不在上市公司担任高级管理人员的董事，其中独立董事应当过半数，并由 独 ...

西藏多瑞医药股份有限公司 总经理工作细则 第一章 总则 第一条 为促进西藏多瑞医药股份有限公司（以下简称"公司"）经营管理的制度化、 规范化、科学化，确保公司经营决策的正确性、合理性，提高民主决策、科学决策水 平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《西藏多瑞医药股份有 限公司章程》（以下简称"公司章程"）及其他的有关法律、法规规定，制订本细则。 第二条 公司依法设置总经理和副总经理、财务负责人等高级管理人员（以下简称 "高管"），高管应当遵守法律、行政法规和公司章程的规定，履行诚信和勤勉的义务， 如负责公司的日常经营管理，总经理对公司董事会负责并报告工作，副总经理、财务 负责人等高级管理人员对总经理负责并报告工作。 第二章 总经理的任免 第三条 总经理任职，应当具备下列条件： （一） 优秀的个人品质：有较强的责任心，积极进取、忠实勤勉、廉洁奉公等。 （二） 良好的职业操守： 1. 具备高度的敬业精神，全力履行好自己的职责，忠实维护公司利益； 2. 严守公司商业秘密，不将公司商业秘密透露给任何未经董事会批准的第三方。 （三） 专业素质与能力：具有丰富的战略规划、经营管理、人际交往等方面的专 ...